Prolonged 1-phenylalanine mustard (L-PAM) administration as an adjuvant to mastectomy in the management of patients with primary breast cancer and pathologically positive axillary nodes was evaluated by a prospective, randomized, clinical trial. Treatment failures occurred in 22 per cent of 108 patients receiving placebo and 9.7 per cent of 103 women given L-PAM (p = 0.01). A statistically significant difference (p = 0.02) existed in favor of L-PAM relative to disease-free interval. In premenopausal women, the difference with respect to disease-free interval of treated and control groups was highly significant (p = 0.008). A treatment failure occurred in 30 per cent of premenopausal patients receiving placebo and 3 per cent of those treated with L-PAM (p = 0.008). Whereas a similar trend was observed in postmenopausal patients, the difference is not statistically significant. Thus, L-PAM has been demonstrated to be effective in the treatment of women with primary breast cancer, particularly those who are premenopausal. Results were achieved with minimal undesirable side effects.
This article has been cited by other articles:
Fisher, B., Redmond, C. K., Fisher, E. R.
(2008). Evolution of Knowledge Related to Breast Cancer Heterogeneity: A 25-Year Retrospective. JCO
26: 2068-2071
[Full Text]
Marks, L. B., Zeng, J., Prosnitz, L. R.
(2008). One to Three Versus Four or More Positive Nodes and Postmastectomy Radiotherapy: Time to End the Debate. JCO
26: 2075-2077
[Full Text]
Kyndi, M., Sorensen, F. B., Knudsen, H., Overgaard, M., Nielsen, H. M., Overgaard, J.
(2008). Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group. JCO
26: 1419-1426
[Abstract][Full Text]
Bonadonna, G., Valagussa, P., Veronesi, U.
(2008). Lessons From the Initial Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil Studies in Operable Breast Cancer. JCO
26: 342-344
[Full Text]
Roche, H., Kerbrat, P., Bonneterre, J., Fargeot, P., Fumoleau, P., Monnier, A., Clavere, P., Goudier, M.-J., Chollet, P., Guastalla, J.-P., Serin, D., On behalf of the French Adjuvant Study Group,
(2006). Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol
17: 1221-1227
[Abstract][Full Text]
Lin, Y.-C., Chen, S.-C., Chang, H.-K., Hsueh, S., Tsai, C.-S., Lo, Y.-F., Hwang, T.-L., Chen, M.-F.
(2005). Identifying Good Prognosis Group of Breast Cancer Patients with 1-3 Positive Axillary Nodes for Adjuvant Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) Chemotherapy. Jpn J Clin Oncol
35: 514-519
[Abstract][Full Text]
Davidson, N. E., O'Neill, A. M., Vukov, A. M., Osborne, C. K., Martino, S., White, D. R., Abeloff, M. D.
(2005). Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node-Positive, Steroid Hormone Receptor-Positive Breast Cancer: Results From INT 0101 (E5188). JCO
23: 5973-5982
[Abstract][Full Text]
Dellapasqua, S., Colleoni, M., Gelber, R. D., Goldhirsch, A.
(2005). Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer. JCO
23: 1736-1750
[Full Text]
Bonadonna, G., Moliterni, A., Zambetti, M., Daidone, M. G., Pilotti, S., Gianni, L., Valagussa, P.
(2005). 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ
330: 217-
[Abstract][Full Text]
Dunn, B. K., Wickerham, D. L., Ford, L. G.
(2005). Prevention of Hormone-Related Cancers: Breast Cancer. JCO
23: 357-367
[Abstract][Full Text]
Cristofanilli, M., Hortobagyi, G. N.
(2004). Breast Cancer Highlights: Key Findings from the San Antonio Breast Cancer Symposium: A U.S. Perspective. The Oncologist
9: 471-478
[Abstract][Full Text]
Fumoleau, P., Kerbrat, P., Romestaing, P., Fargeot, P., Bremond, A., Namer, M., Schraub, S., Goudier, M.-J., Mihura, J., Monnier, A., Clavere, P., Serin, D., Seffert, P., Pourny, C., Facchini, T., Jacquin, J.-P., Sztermer, J.-F., Datchary, J., Ramos, R., Luporsi, E.
(2003). Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial. JCO
21: 298-305
[Abstract][Full Text]
Hortobagyi, G. N
(2001). Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview. J Natl Cancer Inst Monogr
2001: 72-79
[Abstract][Full Text]
Panasci, L., Paiement, J.-P., Christodoulopoulos, G., Belenkov, A., Malapetsa, A., Aloyz, R.
(2001). Chlorambucil Drug Resistance in Chronic Lymphocytic Leukemia: The Emerging Role of DNA Repair. Clin. Cancer Res.
7: 454-461
[Abstract][Full Text]
Fisher, B., Dignam, J., Tan-Chiu, E., Anderson, S., Fisher, E. R., Wittliff, J. L., Wolmark, N.
(2001). Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes. JNCI J Natl Cancer Inst
93: 112-120
[Abstract][Full Text]
Braeuning, M. P., Burke, E. T., Pisano, E. D.
(2000). Embolization Coils as Tumor Markers for Mammography in Patients Undergoing Neoadjuvant Chemotherapy for Carcinoma. Am. J. Roentgenol.
174: 251-252
[Full Text]
Baum, M., Houghton, J.
(1999). Contribution of randomised controlled trials to understanding and management of early breast cancer. BMJ
319: 568-571
[Full Text]
Fisher, B.
(1999). National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial: A Reflective Commentary. JCO
17: 1632-1632
[Full Text]
Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., Wilson, K. S., Knowling, M. A., Coppin, C. M.L., Paradis, M., Coldman, A. J., Olivotto, I. A.
(1997). Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer. NEJM
337: 956-962
[Abstract][Full Text]
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., Brambilla, C.
(1995). Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer -- The Results of 20 Years of Follow-Up. NEJM
332: 901-906
[Abstract][Full Text]
Henderson, I. C.
(1995). Paradigmatic Shifts in the Management of Breast Cancer. NEJM
332: 951-952
[Full Text]
Frei, E 3rd
(1982). The National Cancer Chemotherapy Program. Science
217: 600-606
[Abstract]
HOLLAND, J. F.
(1976). Breast Cancer and Chemotherapy. Science
192: 1062-1063
